Screening for Neoehrlichia mikurensis and other emerging tick-borne pathogens in Swedish patients with systemic lupus erythematosus receiving B-cell-targeted therapies

The management of moderate to severe systemic lupus erythematosus (SLE) has advanced considerably with the introduction of B-cell-targeted therapies. Several emerging tick-borne diseases (eTBDs) have gained increasing attention as causes of febrile illness with potentially serious complications in predominantly immunocompromised, B-cell-depleted individuals. Since the occurrence of eTBDs remains insufficiently studied in SLE, we aimed to determine whether such infections remain undetected among patients living in a tick-endemic region of Southeastern Sweden. Biobanked sera (n = 143) collected during 2015–2024 from 48 SLE patients receiving rituximab or belimumab in Region Östergötland were included. As comparators, samples from patients with quiescent disease on hydroxychloroquine treatment only (n = 50) were analysed. All samples were investigated by real-time polymerase chain reaction assays for the presence of the eTBD pathogens Neoehrlichia mikurensis, Borrelia burgdorferi sensu lato, Borrelia miyamotoi, Anaplasma phagocytophilum, Spiroplasma ixodetis, and Babesia spp. No pathogen-specific DNA for the examined eTBDs was detected in serum samples from the included patients. Evidence suggests that B-cell-targeted therapies may raise eTBD risk; however, none of the individuals with SLE included herein was found to be infected, despite the documented presence of these pathogens in Southeastern Sweden. Our findings contrast with those from Norwegian immunocompromised patients, but are in line with data from the Danish nationwide Rheumatological Database, including patients with arthritis receiving tumour necrosis factor inhibitors. Hypothetically, higher doses of glucocorticoids impair B-cell function and increase the risk of eTBD further. Nevertheless, routine eTBD screening of patients with SLE in Southeastern Sweden is not supported by our data.

Authors

Publication Details

Journal
Figshare
Published
2026-11-12
DOI
https://doi.org/10.6084/m9.figshare.34994294
Primary Topic
Vector-borne infectious diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Screening for Neoehrlichia mikurensis and other emerging tick-borne pathogens in Swedish patients with systemic lupus erythematosus receiving B-cell-targeted therapies

L Labbé Sandelin, J Wetterö, J Sjöwall, AJ Henningsson et al.
Figshare
Vector-borne infectious diseases
article

Screening for Neoehrlichia mikurensis and other emerging tick-borne pathogens in Swedish patients with systemic lupus erythematosus receiving B-cell-targeted therapies

L Labbé Sandelin, J Wetterö, J Sjöwall, AJ Henningsson, C Sjöwall, M Lager, E Ölfvingsson
article en

Abstract

The management of moderate to severe systemic lupus erythematosus (SLE) has advanced considerably with the introduction of B-cell-targeted therapies. Several emerging tick-borne diseases (eTBDs) have gained increasing attention as causes of febrile illness with potentially serious complications in predominantly immunocompromised, B-cell-depleted individuals. Since the occurrence of eTBDs remains insufficiently studied in SLE, we aimed to determine whether such infections remain undetected among patients living in a tick-endemic region of Southeastern Sweden. Biobanked sera (n = 143) collected during 2015–2024 from 48 SLE patients receiving rituximab or belimumab in Region Östergötland were included. As comparators, samples from patients with quiescent disease on hydroxychloroquine treatment only (n = 50) were analysed. All samples were investigated by real-time polymerase chain reaction assays for the presence of the eTBD pathogens Neoehrlichia mikurensis, Borrelia burgdorferi sensu lato, Borrelia miyamotoi, Anaplasma phagocytophilum, Spiroplasma ixodetis, and Babesia spp. No pathogen-specific DNA for the examined eTBDs was detected in serum samples from the included patients. Evidence suggests that B-cell-targeted therapies may raise eTBD risk; however, none of the individuals with SLE included herein was found to be infected, despite the documented presence of these pathogens in Southeastern Sweden. Our findings contrast with those from Norwegian immunocompromised patients, but are in line with data from the Danish nationwide Rheumatological Database, including patients with arthritis receiving tumour necrosis factor inhibitors. Hypothetically, higher doses of glucocorticoids impair B-cell function and increase the risk of eTBD further. Nevertheless, routine eTBD screening of patients with SLE in Southeastern Sweden is not supported by our data.

Figshare
Good health and well-being
Vector-borne infectious diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon